Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.
Complete remission of symptoms and prevention of symptomatic recurrence are among the main therapeutic aims in gastro-oesophageal reflux disease (GORD). In this context, a potent pharmacologic inhibition of gastric acid secretion plays a central role. The goal of antisecretory treatment in GORD is to maintain an intragastric pH greater than 4.0 for the longest possible time. This is best achieved by the administration of proton pump inhibitors (PPIs). Tolerability and safety of different PPIs are similar and consistently high, but therapeutic efficacy may differ among them. Esomeprazole appears to achieve an intragastric pH greater than 4.0 for a larger number of hours compared with any other PPI. This is associated with a greater therapeutic efficacy of esomeprazole compared with omeprazole, lansoprazole and pantoprazole in both complete remission of symptoms and prevention of symptomatic recurrence in GORD. This review provides evidence-based recommendations for the treatment of GORD-related symptoms in clinical practice.
Domínguez-Muñoz
J Enrique
JE
Department of Gastroenterology, University Hospital of Santiago de Compostela, Spain.
Sobrino
Miguel
M
D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D019317:Evidence-Based Medicine; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D054328:Proton Pump Inhibitors; D012720:Severity of Illness Index
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors